# Human Rating Form — GDgpt Clinical Utility Evaluation

> **Instructions**: Rate each question on D1-D5 (1=Poor, 3=Adequate, 5=Excellent).
> Fill in the table below. Use same rubric as the LLM judge.
> Return this file after completion.

## Rubric Summary
- **D1 Factual Accuracy**: Are gene/pathway/drug claims correct?
- **D2 Completeness**: Are key evidence items covered?
- **D3 Traceability**: Are claims attributed to specific sources/edges?
- **D4 Clinical Safety**: Does it acknowledge uncertainty vs. fabricate?
- **D5 Coherence**: Is it logically structured and readable?

---
## Question 1: `pcqa_100c15a0`
**Q**: Which types of cancer can be treated with pomalidomide?

### System A (GDgpt)
```
Pomalidomide is TARGETED_TO TNF, a pro-inflammatory cytokine, and INTERACTS_WITH CYP1A2, CYP3A4, PTGS2, and ABCB1, as confirmed by the knowledge graph. Adenocarcinoma of the liver and intrahepatic biliary tract is ASSOCIATED_WITH pathways such as "Neutrophil Degranulation," "RHO GTPases Activate Formins," and "Resolution of Sister Chromatid Cohesion," which are INVOLVED_IN inflammation and cytoskeletal remodeling. Key genes such as CDK1, AURKB, BIRC5, CENPE, and PLK1 are LINKED_TO these pathways, while inflammatory mediators like SERPINA1, FABP5, and MPO are INVOLVED_IN "Neutrophil Degranulation." Pomalidomide's targeting of TNF suggests a potential mechanism to mitigate cancer-related inflammation, and its interaction with PTGS2 and ABCB1 may further modulate prostaglandin synthesis and d
```

### System B (GPT-4o)
```
Pomalidomide is primarily approved for the treatment of **multiple myeloma**, specifically in adult patients who have received at least two prior therapies (including lenalidomide and a proteasome inhibitor) and have demonstrated disease progression on or after these treatments. 

Pomalidomide is an immunomodulatory agent that works by modulating the immune system, inhibiting angiogenesis, and directly inducing tumor cell apoptosis. It is often used in combination with dexamethasone or other agents, such as daratumumab or carfilzomib, in relapsed or refractory multiple myeloma.

There is ongoing research into its potential use in other malignancies, but its clinical utility outside multiple myeloma is not yet established or FDA-approved.

For specific cases or novel applications, consultat
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 2: `pcqa_116f85c9`
**Q**: What are the drug treatment options for renal cell carcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Treatment options for renal cell carcinoma (RCC) depend on the stage and subtype of the disease (e.g., clear cell RCC vs. non-clear cell RCC) as well as patient-specific factors. Below is a summary of systemic drug treatment classes commonly used in advanced or metastatic RCC:

### 1. **Immune Checkpoint Inhibitors (ICI)**
   - **Anti-PD-1/PD-L1 Therapies**:
     - Nivolumab (anti-PD-1)
     - Pembrolizumab (anti-PD-1)
     - Atezolizumab (anti-PD-L1, less commonly used in RCC)
   - **Combination ICI Therapy**:
     - Nivolumab + Ipilimumab (anti-PD-1 + anti-CTLA-4) for intermediate- and poor-risk clear cell RCC.

### 2. **Tyrosine Kinase Inhibitors (TKIs)**
   - Target vascular endothelial growth factor receptor (VEGFR) pathways, a key driver in RCC angiogenesis.
     - Axitinib
     - Ca
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 3: `pcqa_1a6b6d40`
**Q**: What types of cancer can be treated by dtie?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
As of my knowledge cutoff in October 2023, "DTIE" does not correspond to a recognized therapeutic modality, drug, or biomarker in oncology. It is possible that you may be referring to a specific targeted therapy, immunotherapy, or investigational agent, but more context or clarification is needed to identify it accurately.

If you are referencing a specific novel therapy or approach, please provide additional details or confirm the spelling. For further clarification, consulting updated oncology databases or literature would be necessary.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 4: `pcqa_1a84a43f`
**Q**: What disease does a PDGFRA gene mutation cause?

### System A (GDgpt)
```
Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
A mutation in the **PDGFRA gene** is commonly associated with **gastrointestinal stromal tumors (GISTs)**. Specifically, activating mutations in PDGFRA, typically in exons 12, 14, or 18, lead to constitutive activation of the receptor tyrosine kinase, driving tumor growth. These mutations are seen in a subset of GISTs, often in tumors that arise in the stomach and are KIT-negative. The most frequent PDGFRA mutation is the **D842V mutation in exon 18**, which is associated with resistance to first-line tyrosine kinase inhibitors like imatinib.

If further evidence or specific details are needed, external databases or literature would need to be consulted.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 5: `pcqa_1dfaf3e3`
**Q**: What types of cancer can be treated with avelumab?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Avelumab, a PD-L1 immune checkpoint inhibitor, is FDA-approved for the treatment of the following cancer types:

1. **Metastatic Merkel Cell Carcinoma (MCC):** Approved for the treatment of adults and pediatric patients 12 years and older with metastatic MCC.
   
2. **Locally Advanced or Metastatic Urothelial Carcinoma (UC):** Approved for patients with disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

3. **Maintenance Therapy in Locally Advanced or Metastatic Urothelial Carcinoma:** Approved as first-line maintenance therapy in patients whose disease has not progressed after platinum-based chemotherapy.

4. **Recurrent or Advanced Renal Cell Carcinoma (RCC):** Approved in combination w
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 6: `pcqa_1f3d25f5`
**Q**: What targeted drugs can be used for kidney with VHL gene mutation?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
For kidney cancers, particularly clear cell renal cell carcinoma (ccRCC), which is commonly associated with mutations in the **VHL (Von Hippel-Lindau)** tumor suppressor gene, targeted therapies aim to exploit the downstream effects of VHL inactivation. These include the dysregulation of the **HIF (hypoxia-inducible factor)** pathway and increased angiogenesis. The following targeted drugs are commonly used:

1. **HIF-2α inhibitors**:
   - **Belzutifan (MK-6482)**: A specific HIF-2α inhibitor, approved for treating VHL disease-associated renal cell carcinoma in patients who do not require immediate surgery. It directly targets the primary oncogenic driver in VHL-mutated tumors.

2. **VEGF pathway inhibitors**:
   - **Sunitinib** (multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, etc.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 7: `pcqa_21285043`
**Q**: Is there a strong association between BRCA1 gene mutation and ovarian carcinoma?

### System A (GDgpt)
```
Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Yes, there is a strong association between BRCA1 gene mutations and ovarian carcinoma. Germline mutations in the BRCA1 gene significantly increase the risk of developing high-grade serous ovarian carcinoma (HGSC), the most common and aggressive subtype of epithelial ovarian cancer. Women with BRCA1 mutations have an estimated lifetime risk of ovarian cancer of approximately 39-44%, compared to a 1-2% risk in the general population. BRCA1 mutations impair DNA repair via homologous recombination, leading to genomic instability and carcinogenesis. This association is well-established in clinical and molecular studies.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 8: `pcqa_2f1872cf`
**Q**: What types of cancer is altretamine suitable for treating?

### System A (GDgpt)
```
Altretamine is INDICATED_FOR hereditary breast ovarian cancer syndrome, as confirmed by the knowledge graph. Hereditary breast ovarian cancer syndrome is ASSOCIATED_WITH genes ABCA3, ABCA4, ABCB1, and ABCB10, which belong to the ABC transporter family and may influence cellular transport, drug resistance, and metabolism [LLM-inferred]. The disease is also LINKED_TO pathways such as PI3K/AKT signaling, RAF/MAP kinase cascade, neutrophil degranulation, interleukin-4 and interleukin-13 signaling, and PI5P, PP2A, and IER3 regulation of PI3K/AKT signaling, which regulate cancer cell survival, proliferation, and the tumor microenvironment. While Altretamine is a DNA-alkylating agent that targets rapidly dividing cancer cells, no direct Drug→Gene→Disease or Drug→Pathway links are confirmed in the
```

### System B (GPT-4o)
```
Altretamine is primarily used in the treatment of **recurrent or persistent ovarian cancer**, particularly in patients who have already undergone first-line chemotherapy with a platinum-based regimen. Its use is generally reserved for palliative treatment in this setting. Altretamine is an alkylating agent, and its exact mechanism of action is not fully understood but is thought to involve DNA damage leading to apoptosis. 

For other cancer types, altretamine is not commonly utilized, as more effective treatments are typically available. If additional evidence on its utility for other cancers is needed, external databases or literature would need to be consulted.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 9: `pcqa_300918af`
**Q**: What drugs are available for cancers with ERBB2 mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
ERBB2 (HER2) mutations can be targeted by several therapies, particularly in cancers such as breast, lung, gastric, and others. The following drugs are commonly used or under investigation for ERBB2-mutated cancers:

1. **HER2-Directed Tyrosine Kinase Inhibitors (TKIs):**
   - **Neratinib**: Irreversible pan-HER TKI approved for HER2-positive breast cancer and used off-label for ERBB2-mutated cancers.
   - **Tucatinib**: Selective HER2 TKI, FDA-approved for HER2-positive breast cancer; activity in ERBB2-mutated tumors is being explored.
   - **Lapatinib**: Dual HER2/EGFR TKI, used in HER2-positive breast cancer and occasionally off-label for ERBB2-mutated tumors.
   - **Mobocertinib**: Investigated for ERBB2-mutated cancers, especially in non-small cell lung cancer (NSCLC).
   - **Pyrotini
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 10: `pcqa_33a4873d`
**Q**: What types of cancer can sotorasib treat?

### System A (GDgpt)
```
Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Sotorasib is FDA-approved for the treatment of **KRAS G12C-mutated non-small cell lung cancer (NSCLC)** in adult patients who have received at least one prior systemic therapy. Additionally, it is being investigated in clinical trials for other **KRAS G12C-mutated cancers**, such as colorectal cancer, pancreatic cancer, and other solid tumors. However, its use beyond NSCLC is not yet FDA-approved and remains investigational. Clinical trial data should be reviewed for specific evidence regarding efficacy in other tumor types. 


```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 11: `pcqa_34d11293`
**Q**: What FDA-approved drugs target cancers with ERBB2 mutations?

### System A (GDgpt)
```
ERBB2 is a critical oncogene that is ASSOCIATED_WITH diseases such as breast cancer, breast carcinoma, breast neoplasm, and adenocarcinoma of the liver and intrahepatic biliary tract, as confirmed by the knowledge graph. It encodes a receptor tyrosine kinase involved in the HER2 signaling pathway, where aberrations like mutations or amplification drive oncogenic activity by promoting cell proliferation and survival. Drugs such as Afatinib, Brigatinib, AV-412, and Fostamatinib are TARGETED_AT ERBB2, potentially inhibiting its oncogenic signaling. Afatinib is an FDA-approved irreversible tyrosine kinase inhibitor effective for cancers driven by EGFR and ERBB2 signaling, including non-small cell lung cancer (NSCLC), and is a strong candidate for ERBB2-mutant breast cancer. Brigatinib, another
```

### System B (GPT-4o)
```
FDA-approved drugs targeting cancers with **ERBB2** (HER2) mutations include:

1. **Trastuzumab deruxtecan (Enhertu)** - Approved for HER2-mutant non-small cell lung cancer (NSCLC) and HER2-positive breast cancer.
2. **Neratinib (Nerlynx)** - Approved for HER2-mutant breast cancer and other solid tumors with specific ERBB2 mutations under certain conditions.
3. **Tucatinib (Tukysa)** - Approved for HER2-positive breast cancer, with potential off-label use in HER2-mutant cancers.
4. **Ado-trastuzumab emtansine (Kadcyla)** - Approved for HER2-positive breast cancer but may target HER2 mutations in certain settings.
5. **Fam-trastuzumab deruxtecan (Enhertu)** - Approved for HER2-low and HER2-positive breast cancer, with potential activity in some HER2-mutant tumors.

Further specifics depend 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 12: `pcqa_357a7dee`
**Q**: What types of cancer can be treated with abarelix?

### System A (GDgpt)
```
Prostate cancer is ASSOCIATED_WITH key signaling pathways, including the neutrophil degranulation pathway, Interleukin-4 and Interleukin-13 signaling pathways, PI5P, PP2A, and IER3 regulation of PI3K/AKT signaling, RAF/MAP kinase cascade, and PIP3 activation of AKT signaling, per the knowledge graph. Genes such as ERBB2, EGFR, AKT1, ESR1, and ESR2 are ASSOCIATED_WITH prostate cancer and INVOLVED_IN these pathways, driving tumor cell proliferation, survival, and hormonal signaling critical for cancer progression. Additional genes such as B2M, ALOX5, MME, GSTP1, CTSB, MET, PTGS2, HMOX1, MMP9, and VEGFA are also ASSOCIATED_WITH prostate cancer. Abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, suppresses testosterone production by inhibiting the hypothalamic-pituitary-gonadal (HPG
```

### System B (GPT-4o)
```
Abarelix is a gonadotropin-releasing hormone (GnRH) antagonist that is primarily used for the treatment of advanced prostate cancer. It works by directly suppressing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a rapid reduction in testosterone levels, which is critical for the growth of hormone-sensitive prostate cancer. 

Currently, abarelix is not routinely used for other cancer types, as its mechanism is specific to cancers driven by androgens, such as prostate cancer.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 13: `pcqa_38189cc6`
**Q**: What NMPA-approved drugs are available for cancers with EGFR mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
As of my last knowledge cutoff in October 2023, the National Medical Products Administration (NMPA) in China has approved several drugs targeting EGFR mutations in cancers, primarily non-small cell lung cancer (NSCLC). Below is a list of NMPA-approved drugs for EGFR-mutant cancers:

### First-Generation EGFR Tyrosine Kinase Inhibitors (TKIs):
1. **Gefitinib** (Iressa)
2. **Erlotinib** (Tarceva)
3. **Icotinib** (Conmana) – Developed in China.

### Second-Generation EGFR TKIs:
4. **Afatinib** (Gilotrif)
5. **Dacomitinib** (Vizimpro)

### Third-Generation EGFR TKIs:
6. **Osimertinib** (Tagrisso) – Effective against T790M resistance mutation and first-line treatment for EGFR-mutant NSCLC.

### Combination Therapies and Additional Approvals:
- **Amivantamab** (Rybrevant) – A bispecific antibody
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 14: `pcqa_3ac76474`
**Q**: What types of cancer can ponatinib be used to treat?

### System A (GDgpt)
```
Ponatinib is a multi-target kinase inhibitor that INTERACTS_WITH genes such as KIT, KDR, CYP2D6, CYP3A4, and ABL1, as confirmed by the knowledge graph. KIT and KDR are INVOLVED_IN pathways such as Estrogen-dependent gene expression, PIP3 activates AKT signaling, and the RAF/MAP kinase cascade, which are ASSOCIATED_WITH breast cancer and breast neoplasm. These pathways are critical for tumor proliferation and survival, suggesting that Ponatinib may have potential utility in disrupting these mechanisms in breast cancer and related hereditary conditions such as hereditary breast carcinoma and hereditary breast ovarian cancer syndrome [LLM-inferred]. However, no direct KG-supported evidence exists for Ponatinib TREATING breast cancer or other diseases, and its potential role in squamous cell c
```

### System B (GPT-4o)
```
Ponatinib is primarily used to treat certain types of leukemia, including:

1. **Chronic Myeloid Leukemia (CML)**: Specifically, it is effective in patients with all phases of CML (chronic, accelerated, or blast phase) who are resistant or intolerant to prior tyrosine kinase inhibitors (TKIs). It is particularly notable for its activity against the T315I mutation in the BCR-ABL1 gene, which confers resistance to most other TKIs.

2. **Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)**: Ponatinib is used for patients with Ph+ ALL who are resistant or intolerant to previous TKI therapy.

The efficacy of ponatinib in these cancers is due to its potent inhibition of BCR-ABL1, including resistant mutations such as T315I.

For other cancers, there is limited evidence or on
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 15: `pcqa_3b0a1631`
**Q**: What are the fusion genes in lymphoepithelioma-like carcinoma of the lung?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Lymphoepithelioma-like carcinoma (LELC) of the lung is a rare subtype of non-small cell lung carcinoma (NSCLC) strongly associated with Epstein-Barr virus (EBV) infection, particularly in Asian populations. While fusion genes are not a hallmark of this tumor type, molecular studies occasionally identify alterations relevant to lung cancer.

Reported fusion genes in LELC of the lung are exceedingly rare, but potential fusions, including **ALK, ROS1, and RET rearrangements**, have been sporadically identified. These are more common in other NSCLC subtypes but may occasionally appear in LELC. However, the primary driver in LELC remains EBV infection, not fusion-driven oncogenesis.

If further clarification on specific fusion gene data is required, external databases or literature would need t
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 16: `pcqa_4975f964`
**Q**: What types of cancer are associated with ERBB2-act?

### System A (GDgpt)
```
ERBB2 is ASSOCIATED_WITH breast cancer and its subtypes (e.g., breast carcinoma, breast neoplasm) and INVOLVED_IN key oncogenic pathways, including "Constitutive Signaling by Aberrant PI3K in Cancer," "Constitutive Signaling by Overexpressed ERBB2," and "Downregulation of ERBB2 signaling," per the knowledge graph. In breast cancer, ERBB2 is mechanistically linked to the pathways "PIP3 activates AKT signaling" and "RAF/MAP kinase cascade," which regulate tumorigenesis by promoting cell proliferation and survival. This evidence supports a HIGH confidence level for ERBB2's role in breast cancer. ERBB2 is also ASSOCIATED_WITH adenocarcinoma of the liver and intrahepatic biliary tract, but no KG evidence connects it to specific pathways or mechanisms in this disease, resulting in a LOW confiden
```

### System B (GPT-4o)
```
ERBB2 (HER2) activating alterations (ERBB2-act) are associated with a variety of cancers, including:

1. **Breast Cancer**: Particularly HER2-positive breast cancer, which is driven by ERBB2 amplification or overexpression.
2. **Gastric and Gastroesophageal Junction Cancer**: Often characterized by ERBB2 amplification or overexpression.
3. **Lung Cancer**: Especially non-small cell lung cancer (NSCLC) with ERBB2 mutations (e.g., exon 20 insertions).
4. **Colorectal Cancer**: ERBB2 amplification or mutations can be observed, particularly in metastatic settings.
5. **Bladder Cancer**: ERBB2 overexpression or mutations are less common but can be identified.
6. **Ovarian Cancer**: Some cases show ERBB2 amplification.
7. **Endometrial Cancer**: ERBB2 alterations, including amplification, are pr
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 17: `pcqa_5d5827c2`
**Q**: What are the drug treatment options for fallopian tube carcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Fallopian tube carcinoma is typically treated similarly to epithelial ovarian carcinoma, as they share biological and clinical characteristics. Drug treatment options include:

1. **Platinum-based Chemotherapy**:
   - Standard first-line therapy includes a combination of **carboplatin** and **paclitaxel**.
   - Cisplatin may also be used in place of carboplatin in some cases.

2. **PARP Inhibitors** (for BRCA-mutated or homologous recombination deficiency-positive tumors):
   - **Olaparib**, **niraparib**, or **rucaparib** as maintenance therapy following response to platinum-based chemotherapy.

3. **Bevacizumab** (Anti-VEGF therapy):
   - Often combined with first-line chemotherapy or used as maintenance therapy, particularly in advanced or recurrent disease.

4. **Targeted Therapy**:
  
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 18: `pcqa_5fc04bf3`
**Q**: What FDA-approved drugs are available to treat cancers with CD3E mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
As of my knowledge cutoff in October 2023, there are no FDA-approved drugs that specifically target cancers with CD3E mutations. CD3E encodes a component of the T-cell receptor-CD3 complex, which is critical for T-cell activation and immune response. While CD3E mutations may have implications for immune evasion in cancers, no therapies are directly approved for this alteration. 

However, immunotherapy approaches, such as immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 or anti-CTLA-4 antibodies), could potentially be considered depending on the tumor type and broader immune context. The relevance of CD3E mutations in guiding treatment would require further clinical or experimental evidence.

For the most current information, consulting external databases such as MyCancerGenome, OncoKB,
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 19: `pcqa_607f59b1`
**Q**: What FDA-approved drugs are available to treat cancers with GPNMB mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

GPNMB is TARGETED_BY the FDA-approved antibody-drug conjugate Glembatumumab vedotin, as confirmed by the knowledge graph (KG: GPNMB–[TARGETS]–Glembatumumab vedotin). GPNMB is ASSOCIATED_WITH breast and colorectal cancers (KG: GPNMB–[ASSOCIATED WITH]–Disease) and INTERACTS_WITH the pathway "PTK6 promotes HIF1A stabilization" (KG: GPNMB–[INTERACTS WITH]–PTK6 promotes HIF1A stabilization), which is involved in hypoxia-response signaling. Hypoxia pathways are known to mediate tumor progression and survival [LLM-inferred], supporting GPNMB's role in oncogenesis. However, no KG-supported evidence links GPNMB mutations to Glembatum
```

### System B (GPT-4o)
```
As of my last knowledge cutoff in October 2023, there are **no FDA-approved drugs specifically targeting cancers with GPNMB (glycoprotein nonmetastatic B) mutations**. However, GPNMB has been studied as a potential therapeutic target due to its role in tumor progression and metastasis in certain cancers.

One notable therapy linked to GPNMB is **glembatumumab vedotin (CDX-011)**, an antibody-drug conjugate targeting GPNMB. While it showed promise in clinical trials for breast cancer (particularly triple-negative breast cancer with high GPNMB expression), it has not received FDA approval due to mixed trial results. 

If you are seeking the latest updates or investigational therapies, consulting recent clinical trial databases such as ClinicalTrials.gov or updated FDA resources is recommende
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 20: `pcqa_6915ac3c`
**Q**: How would you describe ezatiostat?

### System A (GDgpt)
```
** Ezatiostat is TARGETS GSTP1, a gene ASSOCIATED_WITH multiple cancers, including Adenocarcinoma of liver and intrahepatic biliary tract, Breast cancer, Breast carcinoma, Breast neoplasm, and Familial prostate carcinoma, per the knowledge graph. GSTP1 is INTERACTS_WITH pathways such as Detoxification of Reactive Oxygen Species, Glutathione Conjugation, and Neutrophil Degranulation, which are critical for oxidative stress management and cellular homeostasis. Mechanistically, Ezatiostat inhibits GSTP1 activity, disrupting these antioxidative pathways and leading to an accumulation of reactive oxygen species (ROS) within cancer cells. This increased oxidative stress compromises cellular integrity and promotes apoptosis, serving as a potential anti-cancer mechanism. Confidence Level: HIGH (ba
```

### System B (GPT-4o)
```
Ezatiostat (also known as TLK199) is a small-molecule glutathione analog that functions as a glutathione S-transferase P1-1 (GSTP1-1) inhibitor. GSTP1-1 is overexpressed in various cancers and is involved in detoxification pathways that contribute to tumor cell survival, drug resistance, and proliferation. By inhibiting GSTP1-1, ezatiostat promotes the accumulation of reactive oxygen species (ROS), leading to apoptosis and reduced proliferation in cancer cells. It has been primarily studied in myelodysplastic syndromes (MDS) for its ability to stimulate hematopoiesis and improve cytopenias. Further clinical evidence and ongoing research are necessary to clarify its broader therapeutic potential.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 21: `pcqa_6aa07609`
**Q**: What type of genetic disease can be caused by cancers with PPM1D mutation?

### System A (GDgpt)
```
Mutations in **PPM1D**, a gene encoding a serine/threonine phosphatase, are ASSOCIATED_WITH **breast cancer** and its subtypes, including **hereditary breast carcinoma** and **hereditary breast ovarian cancer syndrome** (KG: PPM1D–associated with–Breast Cancer, Hereditary Breast Carcinoma, Hereditary Breast Ovarian Cancer Syndrome). These mutations impair the DNA damage response, particularly by attenuating the p53 pathway [LLM-inferred], which reduces p53-mediated apoptosis and promotes tumorigenesis. **PPM1D** is also INTERACTS_WITH the pathway **Transcriptional regulation by RUNX2** (KG: PPM1D–interacts with–Transcriptional regulation by RUNX2), which is implicated in cellular differentiation and tumor progression. Additionally, **PPM1D** mutations may indirectly influence other breast 
```

### System B (GPT-4o)
```
Cancers with PPM1D mutations are associated with a **somatic genetic disease** rather than a hereditary one. Somatic mosaic-activating mutations in the **PPM1D** gene, which encodes a serine/threonine phosphatase, are typically acquired in tumor cells and not inherited. These mutations often lead to loss of the wild-type phosphatase's normal regulatory function, including its role in controlling the DNA damage response through the p53 pathway. This can result in increased tumor cell survival and genomic instability.

PPM1D mutations have been implicated in several cancers, including:

- **Breast cancer**
- **Ovarian cancer**
- **Gliomas**
- **Hematologic malignancies** (e.g., myelodysplastic syndromes and acute myeloid leukemia)

Additionally, PPM1D mutations have been associated with **cl
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 22: `pcqa_76b9d13c`
**Q**: What diseases are associated with the cancers with ERCC2 gene mutations?

### System A (GDgpt)
```
ERCC2 is ASSOCIATED_WITH colorectal cancer, colorectal carcinoma, colorectal neoplasm, and familial prostate carcinoma per the knowledge graph. Mechanistically, ERCC2 mutations impair nucleotide excision repair (NER), leading to genomic instability and increased cancer susceptibility (KG: ERCC2–NER repair impairment–genomic instability). In colorectal cancers, ERCC2 is INVOLVED_IN pathways such as neutrophil degranulation, interleukin-4 and interleukin-13 signaling, degradation of the extracellular matrix, G alpha (i) signaling events, and Ub-specific processing proteases, which contribute to inflammation, tumor progression, invasion, metastasis, and defects in DNA repair and proteostasis. In colorectal carcinoma, ERCC2 is also INVOLVED_IN ABC-family proteins mediated transport and the RHO
```

### System B (GPT-4o)
```
ERCC2 gene mutations are primarily associated with cancers that arise due to defects in the nucleotide excision repair (NER) pathway, which is crucial for repairing DNA damage caused by ultraviolet (UV) light and chemical agents. Diseases associated with ERCC2 mutations include:

1. **Bladder Cancer**: ERCC2 mutations are commonly identified in muscle-invasive bladder cancer (MIBC). These mutations can impair DNA repair, leading to increased genomic instability and cancer susceptibility.

2. **Lung Cancer**: ERCC2 mutations have been implicated in non-small cell lung cancer (NSCLC), particularly in individuals exposed to tobacco smoke, which introduces DNA damage requiring NER for repair.

3. **Head and Neck Squamous Cell Carcinoma (HNSCC)**: ERCC2 mutations have been observed in subsets o
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 23: `pcqa_7dc23489`
**Q**: What are the fusion genes in melanoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Fusion genes in melanoma are rare but have been identified in certain subsets of the disease, particularly in acral, mucosal, and spitzoid melanomas. The most commonly reported fusion genes in melanoma include:

1. **BRAF Fusions:**
   - Examples: **PAPSS1-BRAF**, **KIAA1549-BRAF**, and others.
   - These fusions activate the MAPK pathway and may confer sensitivity to MEK inhibitors.

2. **RET Fusions:**
   - Examples: **CCDC6-RET** and **NCOA4-RET**.
   - RET fusions are detected in a subset of melanomas and can be targeted with RET inhibitors.

3. **ALK Fusions:**
   - Examples: **EML4-ALK**, **TGF-ALK**, and others.
   - ALK fusions are more common in spitzoid melanomas and may respond to ALK inhibitors like crizotinib.

4. **ROS1 Fusions:**
   - Examples: **SLC34A2-ROS1** and **CD74-RO
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 24: `pcqa_7fb69b75`
**Q**: What genetic diseases can cancers with PALB2 mutations cause?

### System A (GDgpt)
```
The gene PALB2 is ASSOCIATED_WITH multiple hereditary cancers, including breast cancer, familial prostate carcinoma, and hereditary breast ovarian cancer syndrome, as confirmed by the knowledge graph (KG: PALB2–associated with–breast cancer, PALB2–associated with–familial prostate carcinoma, PALB2–associated with–hereditary breast ovarian cancer syndrome). PALB2 is a tumor suppressor gene critical for DNA damage repair through homologous recombination, and its mutations lead to genomic instability [LLM-inferred]. In breast cancer, PALB2 mutations are ASSOCIATED_WITH the Estrogen-dependent gene expression pathway and the PIP3 activates AKT signaling pathway (KG: breast cancer–associated with–Estrogen-dependent gene expression, breast cancer–associated with–PIP3 activates AKT signaling), bot
```

### System B (GPT-4o)
```
Cancers with **PALB2 mutations** are associated with an increased risk of certain malignancies due to PALB2’s role in DNA repair via homologous recombination. Germline **PALB2 mutations** are particularly linked to the following cancer risks:

1. **Breast Cancer**: PALB2 is considered a moderate to high-risk gene for hereditary breast cancer. Women with germline PALB2 mutations have a significant lifetime risk, estimated at 33-58% depending on family history.

2. **Ovarian Cancer**: PALB2 mutations are associated with a moderately increased risk of ovarian cancer, though at a lower magnitude compared to BRCA mutations.

3. **Pancreatic Cancer**: Germline PALB2 mutations are implicated in hereditary pancreatic cancer syndromes, with an elevated lifetime risk of developing pancreatic adenoca
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 25: `pcqa_82675eff`
**Q**: What types of cancer are associated with EGFR?

### System A (GDgpt)
```
EGFR is ASSOCIATED_WITH breast cancer, breast carcinoma, breast neoplasm, adenocarcinoma of liver and intrahepatic biliary tract, and hepatocellular carcinoma per the knowledge graph. In breast cancer, EGFR is INVOLVED_IN key oncogenic pathways, including "PIP3 activates AKT signaling," "RAF/MAP kinase cascade," "Estrogen-dependent gene expression," "Interleukin-4 and Interleukin-13 signaling," and "Neutrophil degranulation," which collectively promote tumor growth, immune modulation, and resistance to apoptosis. In adenocarcinoma of the liver and intrahepatic biliary tract, EGFR is INVOLVED_IN pathways such as "Resolution of Sister Chromatid Cohesion," "Separation of Sister Chromatids," "RHO GTPases Activate Formins," "Neutrophil degranulation," and "Amplification of signal from unattache
```

### System B (GPT-4o)
```
Epidermal Growth Factor Receptor (EGFR) is associated with several types of cancer, primarily those with dysregulated EGFR signaling due to mutations, amplifications, or overexpression. Key cancers include:

1. **Non-Small Cell Lung Cancer (NSCLC)**: EGFR mutations (e.g., exon 19 deletions and exon 21 L858R point mutations) are common in adenocarcinomas and are targetable with EGFR tyrosine kinase inhibitors (TKIs).
   
2. **Colorectal Cancer (CRC)**: EGFR overexpression is observed in some cases, though KRAS and NRAS mutations must be absent for anti-EGFR therapies like cetuximab and panitumumab to be effective.

3. **Head and Neck Squamous Cell Carcinoma (HNSCC)**: EGFR is frequently overexpressed, and agents like cetuximab are approved for treatment.

4. **Glioblastoma (GBM)**: EGFR amp
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 26: `pcqa_a6aa510c`
**Q**: What genetic mutations are present in nipple neoplasms?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Nipple neoplasms are rare and can include benign lesions, such as papillomas, or malignant conditions like Paget's disease of the nipple and nipple adenocarcinomas. While specific genetic mutations in nipple neoplasms are not well-characterized due to their rarity, the following mutations have been implicated in related breast cancer subtypes or conditions involving the nipple:

1. **Paget's Disease of the Nipple**:
   - Frequently associated with underlying breast ductal carcinoma in situ (DCIS) or invasive breast carcinoma.
   - Common mutations include:
     - **PIK3CA** mutations (activating mutations in the PI3K pathway).
     - **HER2 (ERBB2)** amplification/overexpression (present in a high percentage of cases).
   - Less frequently, mutations in **TP53** and **CDH1** may also be ob
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 27: `pcqa_a935f450`
**Q**: What are the NMPA-approved drugs for cancers with AR mutation?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
As of my knowledge cutoff in October 2023, the National Medical Products Administration (NMPA) of China has approved several androgen receptor (AR)-targeting drugs for cancers, particularly prostate cancer, which commonly exhibits AR mutations or overexpression. However, AR mutations can influence drug sensitivity or resistance. Below is a list of NMPA-approved drugs targeting the AR pathway:

1. **Enzalutamide**: A second-generation AR inhibitor that prevents AR signaling by blocking ligand binding and nuclear translocation. Approved for metastatic castration-resistant prostate cancer (mCRPC).

2. **Abiraterone acetate**: An androgen biosynthesis inhibitor that blocks CYP17A1, reducing androgen production. Approved for mCRPC and high-risk metastatic hormone-sensitive prostate cancer (mHSP
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 28: `pcqa_a9569cec`
**Q**: What is the relationship between esophageal carcinoma and RARA?

### System A (GDgpt)
```
**RARA** is ASSOCIATED_WITH the pathway **Activation of anterior HOX genes in hindbrain development during early embryogenesis**, INVOLVED_IN the **Nuclear Receptor transcription pathway**, and INVOLVED_IN the **SUMOylation of intracellular receptors**, as confirmed by the knowledge graph. These pathways are known to regulate transcriptional activity and cellular differentiation, which are broadly relevant to cancer biology. However, the knowledge graph provides no evidence linking **RARA** to **esophageal carcinoma**, its associated pathways, or phenotypes such as abdominal distention or pain. Dysregulated transcription, a hallmark of many cancers including esophageal carcinoma, suggests a potential mechanistic relevance of **RARA** [LLM-inferred]. Confidence in this mechanism is **LOW**,
```

### System B (GPT-4o)
```
RARA (retinoic acid receptor alpha) is a nuclear receptor involved in regulating gene expression, particularly those linked to cell differentiation, proliferation, and apoptosis. In esophageal carcinoma, RARA alterations—such as overexpression, mutations, or epigenetic dysregulation—have been implicated in tumor progression and chemoresistance.

Key points on the relationship include:

1. **Dysregulated Expression**: RARA overexpression has been observed in some cases of esophageal cancer and may contribute to tumor cell proliferation and survival through altered retinoic acid signaling.
   
2. **Chemoresistance**: Aberrant RARA signaling may play a role in resistance to chemotherapy by interfering with apoptotic pathways or promoting epithelial-to-mesenchymal transition (EMT).

3. **Poten
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 29: `pcqa_ab8d64d5`
**Q**: Which cancers are associated with cancers with FLT3 mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
FLT3 mutations are primarily associated with hematologic malignancies, particularly:

1. **Acute Myeloid Leukemia (AML):** FLT3 mutations, including internal tandem duplications (FLT3-ITD) and tyrosine kinase domain (TKD) point mutations, are among the most common mutations in AML, occurring in ~30% of cases. These mutations are associated with a poor prognosis, particularly FLT3-ITD.

2. **Acute Lymphoblastic Leukemia (ALL):** FLT3 mutations are less common in ALL but have been reported, particularly in subtypes like B-cell ALL and T-cell ALL.

3. **Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML):** FLT3 mutations are rare but can occur, particularly in cases that progress to AML.

FLT3 mutations are primarily seen in hematologic cancers and are not typically as
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 30: `pcqa_ae56464f`
**Q**: What types of cancer can aldesleukin treat?

### System A (GDgpt)
```
Aldesleukin targets **IL2RA** and enzymatically interacts with **PTGS2** and **PLA2G4A** (KG: Aldesleukin–Target–IL2RA; Aldesleukin–Enzyme–PTGS2; Aldesleukin–Enzyme–PLA2G4A). **PTGS2** and **PLA2G4A** are ASSOCIATED_WITH **Breast Cancer**, **Squamous Cell Carcinoma of the Corpus Uteri**, and **Schizophrenia** (KG: PTGS2–Associated–Breast Cancer; PTGS2–Associated–Squamous Cell Carcinoma of the Corpus Uteri; PTGS2–Associated–Schizophrenia; PLA2G4A–Associated–Breast Cancer; PLA2G4A–Associated–Squamous Cell Carcinoma of the Corpus Uteri; PLA2G4A–Associated–Schizophrenia). Additionally, **CYP3A4** and **XDH** are ASSOCIATED_WITH **Breast Cancer** and **Squamous Cell Carcinoma of the Corpus Uteri** (KG: CYP3A4–Associated–Breast Cancer; CYP3A4–Associated–Squamous Cell Carcinoma of the Corpus Uter
```

### System B (GPT-4o)
```
Aldesleukin (recombinant IL-2) is FDA-approved for the treatment of the following cancers:

1. **Metastatic Renal Cell Carcinoma (mRCC)**  
   - As a high-dose therapy, aldesleukin can induce durable responses in a small subset of patients.

2. **Metastatic Melanoma (MM)**  
   - High-dose aldesleukin has been shown to achieve durable complete responses in select patients.

For other cancers, aldesleukin is being investigated in clinical trials or used off-label in specific contexts, often in combination with other agents or immunotherapeutic strategies. Evidence for these uses would require consultation with updated clinical trial databases or literature.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 31: `pcqa_b04b8be3`
**Q**: What are the fusion genes in alveolar rhabdomyosarcoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
The fusion genes in alveolar rhabdomyosarcoma (ARMS) are typically **PAX3-FOXO1** (most common) and **PAX7-FOXO1**. These result from chromosomal translocations:

1. **PAX3-FOXO1**: t(2;13)(q35;q14)
2. **PAX7-FOXO1**: t(1;13)(p36;q14)

Both fusion genes drive tumorigenesis by dysregulating transcriptional programs involved in myogenic differentiation and proliferation. Detection of these fusions is a critical diagnostic marker for ARMS.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 32: `pcqa_b2bd9b43`
**Q**: What drugs can treat cancers with MTOR mutations?

### System A (GDgpt)
```
The knowledge graph confirms that MTOR is TARGETED by Everolimus, Fostamatinib, and Pimecrolimus (sources: DrugBank, NCBI). Additionally, Everolimus is ASSOCIATED_WITH several breast cancer-related diseases, including breast cancer, breast carcinoma, breast neoplasm, hereditary breast carcinoma, and hereditary breast ovarian cancer syndrome (source: Neo4j_KG). Mechanistically, breast cancer-related diseases are linked to dysregulation of the mTOR signaling pathway, often driven by MTOR mutations [LLM-inferred]. Everolimus likely exerts its therapeutic effect by inhibiting the hyperactive PI3K/AKT/mTOR signaling pathway underlying tumorigenesis. While Fostamatinib and Pimecrolimus also target MTOR, their clinical relevance for breast cancer or other cancers is not confirmed in the KG and re
```

### System B (GPT-4o)
```
Cancers with **MTOR mutations** often exhibit hyperactivation of the mTOR pathway, which plays a central role in cell growth, proliferation, and survival. Drugs targeting this pathway include:

1. **mTOR Inhibitors**:  
   - **Everolimus** (FDA-approved for certain cancers like renal cell carcinoma, breast cancer, and neuroendocrine tumors)  
   - **Temsirolimus** (approved for renal cell carcinoma)  
   These drugs inhibit mTORC1, which may be effective in cancers driven by activating MTOR mutations.

2. **Dual PI3K/mTOR Inhibitors** (investigational or in clinical trials):  
   - Examples: **Apitolisib (GDC-0980)**, **Dactolisib (BEZ235)**  
   These inhibit both PI3K and mTOR activity, potentially addressing compensatory signaling pathways.

3. **Second-generation mTOR inhibitors (mTORC
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 33: `pcqa_b2f5af9f`
**Q**: Which genetic mutations are related to potential resistance to trametinib?

### System A (GDgpt)
```
Resistance to **Trametinib**, a direct inhibitor of **MAP2K1/MEK1** and **MAP2K2/MEK2** (KG: Trametinib–TARGETS–MAP2K1/2), in cancers involving the **RAF/MAP kinase cascade** (KG: MAP2K1/MAP2K2–INTERACTS_WITH–RAF/MAP kinase cascade) is primarily mediated by activating mutations in **BRAF** (KG: BRAF–INTERACTS_WITH–RAF/MAP kinase cascade). These mutations, such as **BRAF V600E** and non-V600E variants, hyperactivate the pathway, bypassing MEK inhibition. Additionally, altered metabolism of **Trametinib** by enzymes **CYP3A4** and **CYP2C8** (KG: Trametinib–ENZYME–CYP3A4/CYP2C8) may reduce drug bioavailability, further contributing to resistance. Secondary mechanisms, including mutations in **MAP2K1/MEK1** and **MAP2K2/MEK2** (KG: Trametinib–TARGETS–MAP2K1/2), or alternative pathway activati
```

### System B (GPT-4o)
```
Resistance to trametinib, a MEK inhibitor, can arise through several genetic mutations and molecular mechanisms, including:

1. **Upstream Activating Mutations**:
   - **KRAS, NRAS mutations or amplification**: These mutations can reactivate the MAPK pathway downstream of MEK, bypassing the inhibitory effect of trametinib.
   - **BRAF amplification** or **secondary BRAF mutations**: These can enhance signaling through the MAPK pathway despite MEK inhibition.

2. **MEK Mutations**:
   - Acquired mutations in **MAP2K1 (MEK1)** or **MAP2K2 (MEK2)** can lead to conformational changes in MEK, reducing the binding affinity of trametinib or reactivating downstream signaling.

3. **Activation of Parallel Pathways**:
   - Activation of the **PI3K/AKT/mTOR pathway** due to mutations in **PIK3CA**, l
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 34: `pcqa_b67bd8ee`
**Q**: What types of cancer can capecitabine be used to treat?

### System A (GDgpt)
```
Capecitabine is ASSOCIATED_WITH hereditary breast ovarian cancer syndrome as an off-label treatment per the knowledge graph, and its mechanism involves inhibition of thymidylate synthase, disrupting DNA synthesis. For this disease, pathways such as PIP3/AKT signaling, RAF/MAP kinase cascade, and Interleukin-4 and Interleukin-13 signaling are INVOLVED_IN its pathophysiology, while genes such as ERBB2, AKT1, and KIT are ASSOCIATED_WITH the condition. In colorectal cancer, Capecitabine may act on pathways like Neutrophil degranulation and Ub-specific processing proteases, which are INVOLVED_IN immune modulation and DNA repair, respectively, and genes such as TP53 are ASSOCIATED_WITH the disease. For breast cancer, pathways including Estrogen-dependent gene expression, PIP3/AKT signaling, and 
```

### System B (GPT-4o)
```
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) used to treat several cancers, including:

1. **Colorectal cancer**: 
   - Adjuvant treatment for stage III colon cancer following surgery.
   - First-line treatment for metastatic colorectal cancer, either as monotherapy or in combination with other agents.

2. **Breast cancer**: 
   - Metastatic breast cancer, particularly in patients resistant to paclitaxel and anthracycline-based regimens.
   - Combination therapy with docetaxel for patients with advanced or metastatic breast cancer after failure of anthracycline-based chemotherapy.

3. **Gastric cancer**: 
   - In combination with platinum-based agents for advanced or metastatic gastric cancer, including gastroesophageal junction cancers.

4. **Pancreatic cancer** (off-label in 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 35: `pcqa_c19faf50`
**Q**: What genetic mutations are present in adenoid cystic carcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Adenoid cystic carcinoma (ACC) is characterized by a few recurrent genetic alterations:

1. **MYB or MYBL1 gene rearrangements**:
   - The most common alteration involves the **MYB-NFIB fusion gene**, resulting from t(6;9)(q22–23;p23–24) translocation. This fusion leads to overexpression of the MYB transcription factor, which drives tumorigenesis.
   - In some cases, **MYBL1 rearrangements** (a homolog of MYB) may be found as an alternative driver alteration.

2. **NOTCH pathway mutations**:
   - Mutations in **NOTCH1** or **NOTCH2** are present in a subset of ACC cases and are associated with more aggressive disease and worse prognosis.

3. **TP53 mutations**:
   - Rare, but when present, they are often linked to advanced disease stages or higher-grade tumors.

4. **PIK3CA or PTEN mutatio
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 36: `pcqa_c86dc1b8`
**Q**: Which types of cancer can be driven by cancers with E3B1 mutations?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
E3B1, also known as ABI1 (ABL-interactor 1), is a gene involved in cytoskeletal reorganization, cell migration, and signal transduction pathways. Mutations or alterations in E3B1/ABI1 have been associated with cancer, although they are relatively rare drivers. Current evidence links E3B1 mutations to the following cancer types:

1. **Hematological Malignancies**: E3B1 mutations or dysregulation have been implicated in certain leukemias, such as acute lymphoblastic leukemia (ALL), due to its role in ABL1 signaling.

2. **Breast Cancer**: Alterations in E3B1 have been reported in breast cancers, particularly due to its involvement in pathways regulating cell motility and invasion.

3. **Gastrointestinal Cancers**: Evidence suggests that E3B1 mutations or dysfunction may contribute to the pro
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 37: `pcqa_c94bbd49`
**Q**: What types of cancer can aclarubicin treat?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Aclarubicin is an anthracycline antibiotic primarily used in the treatment of hematologic malignancies, particularly **acute myeloid leukemia (AML)**. It is administered as part of chemotherapy regimens to induce remission in AML patients. Additionally, aclarubicin has been investigated for its potential efficacy in other leukemias and myelodysplastic syndromes (MDS), but its use in solid tumors is limited and less well-documented.

Further specifics on its approved indications may require consultation of regulatory guidelines or clinical trial data.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 38: `pcqa_d0b052f8`
**Q**: What are the genetic mutations in lung adenocarcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Lung adenocarcinoma is associated with several genetic mutations and alterations that drive tumorigenesis and may serve as therapeutic targets or prognostic markers. The most common genetic mutations include:

1. **EGFR (Epidermal Growth Factor Receptor):** Activating mutations, especially exon 19 deletions and L858R point mutation in exon 21, are seen in approximately 10–15% of non-squamous NSCLC cases in Western populations and up to 30–50% in Asian populations. EGFR mutations are targetable with tyrosine kinase inhibitors (TKIs).

2. **KRAS:** Mutations occur in about 25–30% of lung adenocarcinomas, with the G12C variant being the most common. KRAS G12C inhibitors (e.g., sotorasib) provide a targeted treatment option.

3. **ALK (Anaplastic Lymphoma Kinase):** Rearrangements (e.g., EML4-
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 39: `pcqa_d4d297ee`
**Q**: What are the drug treatment options for ovarian carcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Drug treatment options for ovarian carcinoma depend on the stage, histological subtype, molecular profile (e.g., BRCA mutation or HRD status), and patient characteristics. Broadly, the options include:

### 1. **Platinum-Based Chemotherapy (Standard of Care)**
   - **Carboplatin** or **cisplatin** combined with **paclitaxel** (first-line treatment).
   - Alternatives: Carboplatin with **docetaxel** for patients intolerant to paclitaxel.

### 2. **PARP Inhibitors (Maintenance Therapy or Treatment for BRCA/HRD-Positive Tumors)**
   - **Olaparib**: For BRCA-mutated tumors (germline or somatic) or as maintenance therapy following platinum response.
   - **Niraparib**: For HRD-positive or all-comer ovarian cancers as maintenance therapy.
   - **Rucaparib**: For BRCA-mutated ovarian cancer (both
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 40: `pcqa_da2476bf`
**Q**: What genetic mutations are present in endocervical adenocarcinoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```

### System B (GPT-4o)
```
Endocervical adenocarcinomas commonly harbor the following genetic mutations and alterations:

1. **KRAS mutations**: Frequently observed, particularly in non-human papillomavirus (HPV)-associated endocervical adenocarcinomas.
   
2. **PIK3CA mutations**: Found in both HPV-associated and non-HPV-associated tumors, often promoting PI3K/AKT/mTOR pathway activation.

3. **TP53 mutations**: More common in non-HPV-associated subtypes, reflecting genomic instability.

4. **ARID1A mutations**: Occasionally present, linked to chromatin remodeling defects.

5. **BRAF mutations**: Rare, but may occur in specific subtypes like gastric-type adenocarcinomas.

6. **ERBB2 (HER2) amplifications/mutations**: Seen in a subset of aggressive cases, especially in gastric-type adenocarcinomas.

7. **HPV-related
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 41: `pcqa_daeed5c9`
**Q**: What are the drug treatment options for gastric cancer?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.  
```
```

### System B (GPT-4o)
```
The drug treatment options for gastric cancer depend on the stage of the disease, molecular profile, and patient-specific factors. Below is a general overview:

### 1. **Chemotherapy**
   - **Perioperative/Adjuvant regimens**:
     - FLOT (5-FU, Leucovorin, Oxaliplatin, Docetaxel)
     - CAPOX (Capecitabine, Oxaliplatin)
     - FOLFOX (5-FU, Leucovorin, Oxaliplatin)
     - 5-FU/Leucovorin or Capecitabine (if monotherapy is required)
   - **Palliative regimens**:
     - EOX (Epirubicin, Oxaliplatin, Capecitabine)
     - DCF (Docetaxel, Cisplatin, 5-FU)
     - Single agents (e.g., Paclitaxel, Docetaxel) in refractory settings

### 2. **Targeted Therapy**
   - **HER2+ tumors**:
     - Trastuzumab (in combination with chemotherapy for advanced/metastatic HER2+ gastric cancer)
     - Trastuzuma
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 42: `pcqa_e37dcecf`
**Q**: What types of cancer can be treated with bortezomib?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Bortezomib, a proteasome inhibitor, is primarily approved for and used in the treatment of the following cancers:

1. **Multiple Myeloma:** Bortezomib is a standard treatment option, either as a monotherapy or in combination with other agents (e.g., lenalidomide, dexamethasone), for newly diagnosed or relapsed/refractory multiple myeloma.

2. **Mantle Cell Lymphoma (MCL):** It is approved for use in patients with relapsed or refractory mantle cell lymphoma.

Emerging evidence and off-label use have explored its potential in other hematologic malignancies (e.g., Waldenström macroglobulinemia, amyloid light-chain [AL] amyloidosis) or solid tumors, but such uses are investigational and not yet standard of care.

Further details on additional applications may require review of specific clinica
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 43: `pcqa_e57f9443`
**Q**: What are the fusion genes in t-lymphoblastic leukemia/lymphoma?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) can harbor various fusion genes, although they are less common compared to other leukemia subtypes. Some of the key fusion genes identified in T-ALL/LBL include:

1. **ETV6-NTRK3**: Rare but can be present in cases with translocations involving the NTRK3 gene.
2. **NOTCH1 fusions**: NOTCH1 is frequently mutated or rearranged in T-ALL, although fusions are less common.
3. **SET-NUP214**: Associated with cryptic deletions or amplifications in some T-ALL cases.
4. **PICALM-MLLT10 (CALM-AF10)**: A recurrent fusion seen in aggressive T-ALL cases.
5. **MLLT10 fusions**: MLLT10 can form fusions with multiple partners, such as MLL, PICALM, and others.
6. **TLX1 (HOX11) and TLX3 (HOX11L2) rearrangements**: These involve translocations leading to aberran
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 44: `pcqa_e705c594`
**Q**: What types of cancer can tukysa be used to treat?

### System A (GDgpt)
```
[Honest degradation] Insufficient KG evidence for this case; recommend external lookup (PubMed / OncoKB / CIViC). Findings below are LLM-inferred and not KG-grounded.

Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
Tukysa (tucatinib) is an oral tyrosine kinase inhibitor that specifically targets HER2. It is FDA-approved for the treatment of:

1. **HER2-positive metastatic breast cancer**: Tukysa is used in combination with trastuzumab and capecitabine for adult patients with HER2-positive metastatic breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

2. **HER2-positive colorectal cancer**: Tukysa is approved in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have received at least one prior anti-cancer regimen.

These approvals are based on clinical trials demonstrating improved progression-free survival and/or overall survival i
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 45: `pcqa_f526b6d9`
**Q**: What genetic diseases may be caused by cancers with SLC37A4?

### System A (GDgpt)
```
**SLC37A4** is known to encode a glucose-6-phosphate transporter and is primarily ASSOCIATED_WITH glycogen storage disease type Ib, which is characterized by glucose metabolism defects and neutropenia [LLM-inferred]. The knowledge graph (KG) confirms that schizophrenia is ASSOCIATED_WITH pathways such as "RAF/MAP kinase cascade," "G alpha (i) signaling events," and "Neutrophil degranulation," while familial prostate carcinoma is ASSOCIATED_WITH "Neutrophil degranulation," and hereditary breast ovarian cancer syndrome is ASSOCIATED_WITH "Interleukin-4 and Interleukin-13 signaling." However, no direct KG evidence links **SLC37A4** to any diseases, pathways, or phenotypes, including cancer-related diseases. While it is hypothesized [LLM-inferred] that metabolic dysregulation caused by **SLC37
```

### System B (GPT-4o)
```
SLC37A4 encodes the glucose-6-phosphate transporter (G6PT), which plays a crucial role in glycogen metabolism and glucose homeostasis. Germline mutations in SLC37A4 are associated with **Glycogen Storage Disease Type Ib (GSD Ib)**, a rare inherited metabolic disorder. While GSD Ib is primarily a genetic disease, cancer-related somatic mutations in SLC37A4 are rare but may occur in the context of tumorigenesis.

Cancers with somatic alterations in **SLC37A4** may contribute to metabolic dysregulation in the tumor microenvironment, potentially promoting cancer progression. However, the link between SLC37A4 mutations in cancer and specific genetic syndromes remains unclear and requires further research.

For clinical interpretation or therapeutic actionability, a case-by-case evaluation is ne
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 46: `pcqa_f888cf0a`
**Q**: What drugs can treat cancers with TERT mutations?

### System A (GDgpt)
```
Continuing analysis — further rounds needed.
```
```

### System B (GPT-4o)
```
TERT (telomerase reverse transcriptase) mutations are commonly associated with increased telomerase activity, which promotes cancer cell immortality. While there are no FDA-approved therapies specifically targeting TERT mutations, the following approaches are being explored:

1. **Telomerase Inhibitors**: 
   - **Imetelstat**: A direct telomerase inhibitor that binds to the RNA template of telomerase and prevents its activity. It is in clinical trials for various cancers.

2. **Immune Checkpoint Inhibitors**:
   - TERT promoter mutations are often associated with increased tumor mutational burden and neoantigen expression. This may make tumors more responsive to immune checkpoint inhibitors such as:
     - **Pembrolizumab (anti-PD-1)**
     - **Nivolumab (anti-PD-1)**

3. **Targeting DNA D
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 47: `pcqa_fb9a2cc6`
**Q**: What genetic diseases can be caused by cancers with PKD1 mutations?

### System A (GDgpt)
```
The knowledge graph confirms that schizophrenia is ASSOCIATED_WITH pathways such as the RAF/MAP kinase cascade, G alpha (i) signaling events, and neutrophil degranulation, involving genes such as IL3, PDGFRB, GRIN1, GRIN2D, GRIN2B, ADORA1, CNR1, CNR2, GABBR1, ADRA2A, FABP5, GSTP1, MMP9, SNAP25, and ALDH3B1. Familial prostate carcinoma is ASSOCIATED_WITH the neutrophil degranulation pathway, involving genes such as B2M, ALOX5, MME, GSTP1, and CTSB. Hereditary breast ovarian cancer syndrome is ASSOCIATED_WITH interleukin-4 and interleukin-13 signaling pathways, involving genes such as NOS2, ALOX5, PTGS2, HMOX1, and MAOA. However, no KG evidence supports any direct links between PKD1 or PKD1 mutations and these diseases, pathways, or phenotypes. While PKD1 mutations are known [LLM-inferred] t
```

### System B (GPT-4o)
```
PKD1 is commonly associated with autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder characterized by the development of kidney cysts. However, PKD1 mutations are not typically classified as drivers of cancer. In the context of cancer, PKD1 mutations are rare and not well established as causative. If these mutations are observed in cancer, they are typically incidental or secondary findings rather than primary drivers of malignancy.

Further investigation using cancer-specific genomic databases or literature would be required to determine any definitive association between PKD1 mutations and specific cancers.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 48: `pcqa_fd8461cb`
**Q**: What types of cancer can lorlatinib be used to treat?

### System A (GDgpt)
```
Lorlatinib is a precision oncology drug indicated for lung cancer, particularly ALK-positive non-small cell lung cancer, as confirmed by the knowledge graph (KG: Lorlatinib–INDICATION–Lung Cancer; Lorlatinib–TARGET–ALK–ASSOCIATED WITH–Lung Cancer). ALK rearrangements or mutations are well-established drivers in certain lung cancer subtypes, and Lorlatinib’s targeting of ALK aligns with its therapeutic role. Additionally, Lorlatinib is INVOLVED_IN key oncogenic pathways such as the RAF/MAP kinase cascade (KG: Lung Cancer–ASSOCIATED WITH–KIT/ERBB2/FGFR2/EGFR/MET–INTERACTS WITH–Pathway) and PI3K/AKT signaling (KG: Lung Cancer–ASSOCIATED WITH–KIT/ERBB2/ESR1/AKT1/FGFR2–INTERACTS WITH–Pathway), further supporting its mechanism of action. While Lorlatinib interacts with enzymes such as CYP3A5, CY
```

### System B (GPT-4o)
```
Lorlatinib is primarily used to treat **ALK-positive non-small cell lung cancer (NSCLC)**. It is approved for patients with metastatic NSCLC whose tumors are ALK (anaplastic lymphoma kinase)-positive, particularly in cases where the disease has progressed on prior ALK inhibitor therapy (e.g., crizotinib, alectinib, or ceritinib). Lorlatinib is also effective against some ROS1-positive NSCLC, although this use may be off-label and less common. Further exploration of its efficacy in other cancer types would require external evidence.
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 49: `pcqa_ff4bc2fa`
**Q**: What are the targeted drugs for cancers with PIK3CA mutation?

### System A (GDgpt)
```
PIK3CA is CONFIRMED_TO_BE targeted by Alpelisib, a selective PI3Kα inhibitor, per the knowledge graph (KG: PIK3CA–target–Alpelisib). PIK3CA mutations are [LLM-inferred] to drive cancer progression through hyperactivation of the PI3K/AKT/mTOR signaling pathway, and Alpelisib is APPROVED_FOR use in hormone receptor-positive (HR+) breast cancer harboring PIK3CA mutations. While ATP and Caffeine are also CONFIRMED_TO_TARGET PIK3CA (KG: PIK3CA–target–ATP, PIK3CA–target–Caffeine), they lack therapeutic relevance. Fostamatinib is CONFIRMED_TO_TARGET multiple genes associated with cancers (e.g., KIT, ERBB2, ABL1) (KG: Fostamatinib–target–multiple genes–cancers), but no direct evidence links it to PIK3CA mutations or PIK3CA-driven cancers. Confidence level: MEDIUM, due to partial KG coverage and re
```

### System B (GPT-4o)
```
Targeted drugs for cancers with PIK3CA mutations include:

1. **Alpelisib (Piqray)**: A PI3Kα-specific inhibitor approved for HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations in combination with endocrine therapy (e.g., fulvestrant).

2. **Taselisib** and **GDC-0077**: Investigational PI3K inhibitors for PIK3CA-mutant cancers, primarily in clinical trial settings.

3. **Buparlisib (BKM120)**: A pan-PI3K inhibitor evaluated in clinical trials but with limited success due to toxicity concerns.

4. **Copanlisib (Aliqopa)**: A pan-class I PI3K inhibitor approved for relapsed follicular lymphoma but under investigation for PIK3CA-mutant cancers.

5. **Idelalisib (Zydelig)**: Approved for certain hematologic malignancies (e.g., CLL), though its use in solid tumors with PIK
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |
